FluWatch report: February 9 to 15, 2020 (week 07)
- Influenza activity remained high in week 07; however, the majority of indicators remained similar or decreased slightly from the previous week.
- Influenza A(H1N1) is currently the dominant influenza A subtype circulating in Canada, representing 83% of subtyped influenza A specimens in week 07.
- The highest cumulative hospitalization rates are among children under 5 years of age and adults 65 years of age and older.
- The Sentinel Practitioner Surveillance Network (SPSN) has published interim estimates of vaccine effectiveness which indicate that the 2019/2020 influenza vaccine has provided substantial protection against medically-attended influenza illness in the early part of the season in Canada. Within-season vaccine effectiveness (VE) was estimated to be 58% for any influenza, 44% for A(H1N1), 62% for A(H3N2), and 69% for influenza B.
On this page
- Influenza/ILI Activity (geographic spread)
- Laboratory Confirmed Influenza Detections
- Syndromic/Influenza-like Illness Surveillance
- Influenza Outbreak Surveillance
- Severe Outcomes Influenza Surveillance
- Influenza Strain Characterizations
- Antiviral Resistance
- Vaccine Monitoring
- Provincial and International Influenza Reports
Influenza/Influenza-like Illness (ILI) Activity (geographic spread)
During week 07, influenza activity was reported in almost all regions (44 out of 45) in reporting provinces and territories. Among these regions, 40% reported sporadic activity, 56% reported localized activity, and 2% reported widespread activity (Figure 1).
Figure 1 – Map of influenza/ILI activity by province and territory, Canada, week 2020-07
Number of Regions Reporting in Week 07: 45 out of 53
Figure 1 - Text equivalent
|Province||Influenza Surveillance Region||Activity Level|
|P.E.I.||Prince Edward Island||Localized|
|N.S.||Zone 1 - Western||Localized|
|N.S.||Zone 2 - Northern||Localized|
|N.S.||Zone 3 - Eastern||No Activity|
|N.S.||Zone 4 - Central||Localized|
|Que.||Québec et Chaudieres-Appalaches||Localized|
|Que.||Montréal et Laval||Localized|
|Man.||Northern Regional||No Data|
|Man.||Prairie Mountain||No Data|
|Man.||Southern Health||No Data|
Laboratory-Confirmed Influenza Detections
In week 07, the percentage of laboratory tests positive for influenza was similar to the previous two weeks at 29% and remains similar to the peak percentages reported since late December. Influenza A and B continue to co-circulate.
- The percentage of tests positive for influenza B was 13% in week 07. This continues to be more than two times the average (5.3%) for this time of year.
- The percentage of tests positive for influenza A was 16% in week 07, which is similar to the previous six weeks, and below average for this time of year.
- Among subtyped influenza A detections, influenza A(H1N1) accounted for 83% of detections, a similar proportion to the previous two weeks.
To date this season
(weeks 35 to 07), 38,671 laboratory detections of influenza were reported
- 57% (22,035) were influenza A.
- Among subtyped influenza A detections (5,279), A(H1N1) is the predominant subtype this season (64%).
Detailed information on age and type/subtype has been received for 30,142 laboratory-confirmed influenza cases (Table 1). To date this season (weeks 35 to 07):
- Among cases of influenza A(H3N2) (1,662), the largest proportion was in adults 65 years of age and older (46%).
- Cases of influenza B (13,795) were primarily in younger age groups; 57% of cases were under 19 years of age and 30% between 20 and 44 years of age.
- Among cases of influenza A(H1N1) (2,414), 30% of cases were in adults 65 years of age and older, with approximately equal proportions in adults 20-44 years and 45-64 years (~25%).
Figure 2 - Number of positive influenza tests and percentage of tests positive, by type, subtype and report week, Canada, weeks 2019-35 to 2020-07
Number of Laboratories Reporting in Week 07: 35 out of 36
The shaded area indicates weeks where the positivity rate was at least 5% and a minimum of 15 positive tests were observed, signalling the period of seasonal influenza activity.
Figure 2 - Text equivalent
|Surveillance Week||A(Unsubtyped)||A(H3N2)||A(H1N1)pdm09||Influenza B||Percent Positive A||Percent Positive B|
Figure 3 – Distribution of positive influenza specimens by type/subtype and province/territoryFootnote *, Canada, weeks 2019-35 to 2020-07
- Footnote *
Specimens from NWT, YT, and Nvt are sent to reference laboratories in other provinces.
Figure 3 - Text equivalent
|ProvincesTable Figure 3 - Footnote 1||Cumulative (August 25, 2019 to February 15, 2020)|
|A Total||A(H1N1)||A(H3N2)||A(UnS)Table Figure 3 - Footnote 3||B Total||A & B Total|
|PercentageTable Figure 3 - Footnote 2||57%||15%||9%||72%||43%||100%|
|Cumulative (August 25, 2019 to February 15, 2020)|
|Influenza A||B||Influenza A and B|
|A Total||A(H1N1)||A(H3N2)||A (Un subtyped)Table 1 Footnote 1||Total||#||%|
Syndromic / Influenza-like Illness Surveillance
Healthcare Professionals Sentinel Syndromic Surveillance
In week 07, 1.4% of visits to healthcare professionals were due to influenza-like illness (ILI) which is below the average for this time of year (Figure 4).
Figure 4 – Percentage of visits for ILI reported by sentinels by report week, Canada, weeks 2019-35 to 2020-07
Number of Sentinels Reporting in Week 07: 90
The shaded area represents the maximum and minimum percentage of visits for ILI reported by week from seasons 2014-2015 to 2018-2019
Figure 4 - Text equivalent
The proportion of FluWatchers participants reporting symptoms of cough and fever decreased in week 07 compared to the previous week. In week 07, 3,044 participants reported to FluWatchers, of which 2.6% (79) reported symptoms of cough and fever (Figure 5).
Among the 79 participants who reported cough and fever:
- 22% consulted a healthcare professional;
- 66% reported days missed from work or school, resulting in a combined total of 187 missed days of work or school.
Figure 5 - Percentage of participants reporting fever and cough, Canada, weeks 2019-40 to 2020-07
Number of Participants Reporting in Week 07: 3,044
Figure 5 - Text equivalent
|Surveillance Week||% cough and fever|
Online Figure – Geographic distribution of FluWatchers participants reporting cough and fever, Canada, week 2020-07
Click on the map to access the link
Influenza Outbreak Surveillance
In week 07, a total of 31 outbreaks were reported: 20 in long term care facilities, 10 in facilities categorized as ‘other', which includes facilities such as private personal care homes, correctional facilities, and colleges/universities, and one in a school/daycare (Figure 6). In addition, 7 ILI outbreaks in schools/daycares were reported.
To date this season, a total of 702 laboratory-confirmed influenza outbreaks have been reported; 61% (430) in long-term care facilities, 26% (185) in facilities categorized as ‘other’, 11% (74) in acute care facilities, and 2% (13) in schools/daycares. Of the 668 outbreaks where influenza type was reported, 88% (588) were due to influenza A. Among the 264 outbreaks for which the influenza A subtype was reported, 52% (136) were associated with A(H3N2). To date this season, 119 ILI outbreaks in schools/daycares have also been reported.
Figure 6 – Number of new outbreaks of laboratory-confirmed influenza by report week, Canada, weeks 2019-35 to 2020-07
Number of provinces and territories reporting in week 07: 11 out of 13
Figure 6 - Text equivalent
|Surveillance Week||Acute Care Facilities||Long Term Care Facilities||Other||Schools and Daycares||Remote and/or Isolated Communities|
Severe Outcomes Influenza Surveillance
Provincial/Territorial Influenza Hospitalizations and Deaths
To date this season, 1,687 influenza-associated hospitalizations were reported by participating provinces and territories1.
- 65% of the cases were associated with influenza A.
- Of the 786 cases for which subtype was reported, 61% were associated with influenza A(H3N2).
- The highest cumulative hospitalization rates up to week 07 were among children under 5 years of age and adults 65 years of age and older (54/100,000 population).
189 ICU admissions and 64 deaths have been reported.
- 65% of the ICU admissions and 72% of the deaths were associated with influenza A.
Figure 7 – Cumulative rates of influenza-associated hospitalizations by age-group and surveillance week, Canada, participating provinces and territoriesFootnote 1 weeks 2019-35 to 2020-07
Number of provinces and territories reporting in week 07: 8 out of 9
- Footnote ‡
Influenza-associated hospitalizations are reported by Alberta, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Prince Edward Island and Yukon. Only hospitalizations that require intensive medical care are reported by Saskatchewan.
Figure 7 - Text equivalent
|Surveillance Week||0-4 yrs||5-19 yrs||20-44 yrs||45-64 yrs||65+ yrs|
Pediatric Influenza Hospitalizations and Deaths
In week 07, 69 pediatric (≤16 years of age) laboratory-confirmed influenza-associated hospitalizations were reported by the Immunization Monitoring Program Active (IMPACT) network (Figure 8). The number of cases due to influenza B remains high; however, in recent weeks, a growing proportion of cases have been due to influenza A.
The elevated number of cases this season compared to previous seasons is likely due to the concurrent circulation of influenza A and B. The number of influenza A-associated pediatric hospitalizations is above the average for this time of year which is expected when A(H1N1) is the predominant circulating virus. The number of hospitalizations with influenza B remains well above average compared to previous seasons.
To date this season (weeks 35 to 07):
- 951 pediatric hospitalizations have been reported by the IMPACT network, of which 51% (483) were associated with influenza A and 49% (468) with influenza B.
- The largest proportion of hospitalizations (65%) were among children under 5 years of age (Figure 9).
- 140 ICU admissions were reported, of which 52% were associated with influenza A.
- Less than five pediatric deaths have been reported.
Figure 8 – Number of pediatric (≤16 years of age) hospitalizations reported by the IMPACT network, by week, Canada, weeks 2019-35 to 2020-07
The shaded area represents the maximum and minimum number of cases reported by week from seasons 2014-15 to 2018-19
Figure 8 - Text equivalent
Figure 9 - Text Description
Adult Influenza Hospitalizations and Deaths
Surveillance of laboratory-confirmed influenza-associated adult (≥16 years of age) hospitalizations by the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network began on November 1st for the 2019-20 season.
To date this season, 581 hospitalizations, 53 intensive care unit admissions, and 25 deaths have been reported (Figure 10).
- The majority of hospitalizations have been due to influenza A (82%), and among those subtyped (162) 91% were influenza A(H1N1).
- Among the 476 cases with influenza A, the largest proportion of hospitalizations were in adults 65-79 years of age (35%) and adults 80 years of age and older (32%). Among the 103 cases with influenza B, 33% were between 16 and 34 years of age (Figure 11).
- 87% of hospitalized cases reported at least one type of comorbid condition.
Figure 10 - Text Description
|Surveillance Week||Number of Hospitalizations|
Figure 11 - Text Description
|Age Group||Total hospitalizations|
Influenza Strain Characterizations
From September 1, 2019 to February 20, 2020, the National Microbiology Laboratory (NML) has characterized 692 influenza viruses (355 A(H1N1), 155 A(H3N2) and 182 influenza B) that were received from Canadian laboratories.
Over recent years, circulating strains of A(H3N2) have evolved, and are increasingly difficult to characterize by hemagglutination inhibition (HI) assay. Genetic characterization is established by sequencing the hemagglutinin (HA) gene of the influenza viruses to compare their genetic properties.
Among the 51 influenza A(H3N2) viruses antigenically characterized to date, the majority (80%) showed reduced titer by HI assay to A Kansas/14/2017 using antiserum raised against egg-propagated A Kansas/14/2017. Ten viruses were characterized as A Kansas/14/2017-like (Figure 12 a).
Nearly all (98%) of the 135 A(H3N2) viruses genetically characterized this season belonged to genetic group 3C.2a1b based on sequence analysis of the HA gene. Three viruses belonged to the genetic group 3C.3a (Figure 13).
Group 3C.2a1b viruses analysed represent:
- 90% (28 out of 31) viruses that were also antigenically characterized.
- 100% (104 out of 104) viruses which did not grow to sufficient hemagglutination titer for antigenic characterization by HI assay.
A/Kansas/14/2017 belongs to genetic group 3C.3a and is the influenza A(H3N2) component of the 2019-20 Northern Hemisphere influenza vaccine.
Among the 355 A(H1N1) viruses characterized to date, 57% were antigenically similar to A/Brisbane/02/2018 by HI testing using antiserum raised against egg-propagated A/Brisbane/02/2018 (Figure 12 b).
A/Brisbane/02/2018 is the influenza A(H1N1)component of the 2019-20 Northern Hemisphere influenza vaccine.
Among the 182 influenza B viruses antigenically characterized this season, the vast majority (180) belonged to the B/Victoria lineage. Two viruses were antigenically characterized as similar to B/Phuket/3073/2013 (B/Yamagata lineage).
The majority (89%, 161) of B/Victoria lineage viruses showed reduced titer by HI assay to B/Colorado/06/2017 using antiserum raised against cell culture-propagated B/Colorado/06/2017 (Figure 12c).
Sequence analysis of 150 B/Victoria lineage viruses with reduced titre to B/Colorado/06/2017 showed that 100% had a three amino acid deletion (162-164) in the HA gene. Sequencing is pending for the remaining viruses.
The recommended influenza B components for the 2019-20 Northern Hemisphere influenza vaccine are B/Colorado/06/2017 (Victoria lineage) and B/Phuket/3073/2013 (Yamagata lineage). B/Phuket/3073/2013 is included in the quadrivalent influenza vaccine.
Figure 12 - Text Description
|Number of viruses characterized: 51|
|Antigenic phenotype of A(H3N2) virus||Number of viruses||Percentage|
|Reduced titer to A/Kansas/14/2017||41||80%|
|Number of viruses characterized: 355|
|Antigenic phenotype of A(H1N1) virus||Number of viruses||Percentage|
|Reduced titer to A/Brisbane/02/2018||154||43%|
|Number of viruses characterized: 182|
|Antigenic phenotype of influenza B virus||Number of viruses||Percentage|
|Reduced titer to B/Colorado/06/2017||161||88%|
Figure 13 - Text Description
|Number of viruses sequenced: 135|
|Genetic Clade of A(H3N2) virus||Number of viruses||Percentage|
The National Microbiology Laboratory (NML) also tests influenza viruses received from Canadian laboratories for antiviral resistance. From September 1, 2019 to February 20, 2020, the following results were reported:
486 influenza viruses (140 A(H3N2), 164 A(H1N1) and 182 B) were tested for resistance to oseltamivir:
- All influenza A(H3N2) and B viruses were sensitive to oseltamivir.
- Among the A(H1N1) viruses tested, 163 (99%) were sensitive to oseltamivir and one virus was resistant to oseltamivir with the H275Y mutation in the neuraminidase gene.
486 influenza viruses (140 A(H3N2), 164 A(H1N1) and 182 B) were tested for resistance to zanamivir:
- All influenza viruses tested were sensitive to zanamivir.
High levels of resistance to amantadine persist among influenza A(H1N1) and influenza A(H3N2) viruses. All viruses tested this season were resistant.
Vaccine monitoring refers to activities related to the monitoring of influenza vaccine coverage and effectiveness.
The Canadian Sentinel Practitioner Surveillance Network (SPSN) provides estimates of the effectiveness of the seasonal influenza vaccine in preventing medically-attended illness due to laboratory-confirmed influenza among Canadians.
Based on data collected between November 1, 2019 and February 1, 2020, vaccine effectiveness (VE) was estimated to be 58% for any influenza, 44% for A(H1N1), 62% for A(H3N2), and 69% for influenza B. Substantial protection was observed among children 1 to 19 years of age against both influenza A and B. A good level of protection was also observed among working age adults (20-64 yrs) across all influenza types (Table 2). VE among adults 65 years and older, although imprecise due to small numbers, was lower at 18% (95% CI -59 to 58). The SPSN interim estimates are published and available online.
More information on the network and past VE findings can be viewed on the SPSN website.
Updated influenza vaccine effectiveness estimates will be published at the end of the 2019/2020 influenza season. At that time, sufficient data will likely be available to estimate VE by age-group, including adults 65 years and older with greater precision, as well as for influenza A subtypes.
|All ages||1-19 years||20-64 years|
|VE(%) (CI)Table 2 - Footnote *||N||VE(%) (CI)Table 2 - Footnote *||VE(%) (CI)Table 2 - Footnote *|
|All Influenza||58 (47, 66)||2808||74 (59, 84)||55 (41, 66)|
|Influenza A||49 (34, 60)||2128||70 (44, 84)||45 (25, 59)|
|Influenza A(H1N1)||44 (26, 58)||1948|
|Influenza A(H3N2)||62 (37, 77)||1561|
|Influenza B||69 (57, 77)||2080||77 (59, 87)||68 (51, 79)|
|CI: 95% confidence interval
Influenza vaccine coverage estimates for the 2019-20 season are anticipated to be available in February or March 2020.
The data in the FluWatch report represent surveillance data available at the time of writing. All data are preliminary and may change as more reports are received.
To learn more about the FluWatch program, see the Overview of influenza monitoring in Canada page.
For more information on the flu, see our Flu (influenza) web page.
We would like to thank all the Fluwatch surveillance partners participating in this year's influenza surveillance program.
Report a problem or mistake on this page
- Date modified: